Peroxisome proliferator-activated receptors (PPARs) are ligand activated transcription factors that modulate target gene expression in response to endogenous and exogenous ligands. Ligands for the PPARs have been widely developed for the treatment of various diseases including dyslipidemias and diabetes. While targeting selective receptor activation is an established therapeutic approach for the treatment of various diseases, a variety of toxicities are known to occur in response to ligand administration. Whether PPAR ligands produce toxicity via a receptor-dependent and/or off-target-mediated mechanism(s) is not always known. Extrapolation of data derived from animal models and/or in vitro models, to humans, is also questionable. The different toxicities and mechanisms associated with administration of ligands for the three PPARs will be discussed, and important data gaps that could increase our current understanding of how PPAR ligands lead to toxicity will be highlighted.
Peroxisome proliferator-activated receptor-a (PPARa) was the first of three PPARs to be identified, approximately fifteen years ago (Issemann and Green, 1990) . The PPARa was named in large part because it was thought to mediate the phenomenon of increased hepatic peroxisome volume and density, or peroxisome proliferation. This hypothesis was proven correct when the PPARa-null mouse was constructed and shown to be resistant to peroxisome proliferation in response to administration of the PPARa ligands clofibrate and Wy-14,643 (Lee et al., 1995) . Two additional receptors, termed PPARb (also referred to as PPARd) and PPARc were identified shortly after the discovery of PPARa (Dreyer et al., 1992; Kliewer et al., 1994) , as they shared significant sequence homology with PPARa, but are not involved in mediating peroxisome proliferation. The three PPARs are encoded by separate genes, are differentially expressed in various tissues, and are found in all mammalian species examined to date . This suggests that PPARs have evolved to function as critical modulators of physiological homeostasis, by responding to endogenous ligands and transcriptionally regulating genes involved in important biological processes including lipid and glucose metabolism and transport, and associated energy homeostasis.
PPARs belong to the soluble nuclear hormone receptor superfamily. The classic mechanism of action of PPARs is similar to that of other members of this superfamily (Fig. 1A) . In response to ligand binding, PPARs undergo a conformational change in protein structure allowing for dissociation of corepressor proteins such as NCoR that inhibit transcription, coincident with heterodimerization with another nuclear receptor, retinoid X receptor-a (RXRa). Co-activator proteins (e.g., p300/CBP, SRC-1) and histone acetyl transferases (HATs) are recruited to the receptor heterodimer along with RNA polymerase resulting in a relaxing of chromatin to permit transcription of target genes containing the direct repeat-1 (DR1) consensus sequence binding elements for PPARs. Numerous PPAR target genes have been identified in the past fifteen years that are regulated by PPARs (reviewed in Desvergne and Wahli, 1999; Mandard et al., 2004) . Changes in gene expression mediated by PPARs facilitate the complex modulation of intracellular processes required to maintain homeostasis in a constantly changing environment. While this classic mechanism of action is certainly critical for mediating many of the effects induced by PPAR ligands, there are a number of alternative mechanisms that must be considered. For example, in addition to the classic mechanism of action, PPARa and PPARc can interfere directly with NF-jB and AP1 signaling through direct protein-protein interactions (Delerive et al., 1999; Wang et al., 2002) (Fig. 1B) . PPARc-mediated repression of NF-kB target genes that lead to inhibition of inflammation was recently shown to be due to ligand-dependent SUMOylation of PPARc, which causes PPARc to localize to inflammatory gene promoters in association with co-repressors (Pascual et al., 2005) . PPARs can also down-regulate gene expression, through another mechanism that has yet to be elucidated. For example, PPARa is required to mediate downregulation of apolipoprotein CIII mRNA expression as revealed by studies in fibrate-treated PPARa-null mice (Peters et al., 1997b) ; however, the molecular events responsible for this transcription inhibition are not completely understood. A relatively unique mechanism of transcriptional repression has also been described for PPARb (Fig. 1C) , as PPARb can inhibit transcription of PPARa and PPARc gene expression in vitro (Shi et al., 2002) . Studies with fluorescently labeled PPARa and PPARc fusion proteins indicate that PPARs are primarily found in the nucleus, independent of the presence of ligands (Akiyama et al., 2002a) . Recent evidence suggests that in the absence of exogenous ligands in adipocytes, PPARc colocalizes with either co-activators (Fig. 1D ) or co-repressors ( Fig. 1E ) on PPAR target gene promoters facilitating constitutive expression of some target genes (e.g., aP2) while repressing expression of others (e.g., glycerol kinase), respectively . Administration of a PPARc ligand leads to both the classic transcriptional changes in PPARc target genes by causing conformational changes in PPARc, co-repressor release and co-activator recruitment, in addition to indirectly inducing PGC-1a, which destabilizes co-repressor binding to PPARc . It is important to note that considerably less is known about these latter mechanisms of action (Figs. 1B-E) as compared to the classic ligand-receptor mechanism (Fig. 1A) . Even with the classical mechanism, ligands can also differentially effect coactivator and co-repressor recruitment, thus modulating biological activities and possible toxicities through activating subsets of PPAR target genes similar to what has been found with selective androgen receptor modulators (SARMS) and selective estrogen receptor modulators (SERMS). This illustrates the complexity of how the PPARs can modulate transcriptional activity and suggests that the mechanisms underlying PPAR ligand associated toxicity could be due to any one, or combination of these mechanisms. Adding to this complexity are the facts that secondary and tertiary events that result from ligand activation of PPARs can also contribute to the biological changes that occur, and that different ligands for PPARs elicit different biological responses, that may or may not be directly mediated by PPARs.
While many physiological responses induced by PPAR ligands are clearly directly mediated by activating a specific PPAR subtype, there are also examples of effects that could be due to ''off-target'' mechanisms. For example, PPAR ligands can activate kinases that lead to phosphorylation cascades that can trigger transcriptional changes in addition to directly phosphorylating PPARs (reviewed in Diradourian et al., 2005; Gardner et al., 2005) . This could lead to several levels of downstream regulation that could contribute to PPAR ligand toxicity. For example, there is evidence that PPAR ligands can activate ERKs, which could result in both increased signaling through this pathway, but also lead to phosphorylation of PPARs themselves (Fig. 1F) . While it is known that PPARs can be phosphorylated and lead to changes in transcriptional activity based on reporter assays, the functional significance of PPAR phosphorylation on target gene expression in vivo is uncertain. It is possible that phosphorylation of PPARs could alter ligand binding, co-repressor/co-activator recruitment, or heterodimerization with RXRa that could all influence PPARmediated transcription. This is further complicated by reports suggesting that growth factor-mediated signaling might also interact with other kinase signaling resulting in changes in PPAR transcriptional activity (Fig. 1F) . PPAR ligands are also known to have anti-inflammatory effects that could be due to direct inhibition of pro-inflammatory enzymes (Fig. 1G) (Kim et al., 2005a) and inhibition of pro-inflammatory modulators (e.g., iNOS, COX-2, TNFa, etc) (Chawla et al., 2001; Welch et al., 2003) . Interestingly, the anti-inflammatory action of PPAR ligands can be mediated by both PPAR-dependent (Welch et al., 2003) and PPAR-independent mechanisms (Chawla et al., 2001; Kim et al., 2005a; Welch et al., 2003) . It is important to emphasize that in some cases, pharmacological and sometimes suprapharmacological concentrations of ligand are required to cause an anti-inflammatory effect in experimental animal model systems, and thus may not reflect the activity expected with specific receptor activation. This issue will be addressed in more detail later. PPAR ligands are also reported to cause mitochondrial dysfunction (Fig. 1H) . A number of studies have shown that PPARa and PPARc ligands can inhibit oxidative phosphorylation (Brunmair et al., 2004; Keller et al., 1992 Keller et al., , 1993a Martinez et al., 2005; Scatena et al., 2003 Scatena et al., , 2004a Tirmenstein et al., 2002; Zhou and Wallace, 1999) , and since some of these effects were demonstrated using isolated mitochondria that do not express PPARs, this suggests that ligand-induced mitochondrial dysfunction is due to a mechanism that is PPAR independent. However, while there is evidence that PPAR ligands can cause mitochondrial dysfunction leading to inhibition of oxidative phosphorylation, the role of this effect, if any, on specific ligand-induced toxicities is unknown. Lastly, in addition to all of the above described mechanisms that could contribute to PPAR ligandinduced toxicity, it is also worth noting that it is possible that PPAR ligands may interact with other receptors (Fig. 1I) or with other unidentified molecular targets (Fig. 1J) , and that this putative interaction leads to, or contributes to ligand-specific toxicities.
As noted above, PPAR ligand-induced toxicity could be influenced by any number of mechanisms that may or may not be receptor-dependent. While it is tempting to suggest that a specific PPAR ligand would cause toxicity solely through a receptor-mediated mechanism, this may not always be true. PPAR ligand signaling can be influenced by differences in receptor function (e.g., interactions with other proteins, repressive influences, etc.), in addition to events that are not mediated specifically by the receptor (e.g., kinase activation, enzyme inhibition, anti-inflammatory action, mitochondrial dysfunction, etc.). The use of knockout mouse models has been instrumental in delineating receptor-dependent toxicity. For example, PPARa ligand-induced liver cancer clearly requires PPARa since PPARa-null mice are refractory to the development of hepatocellular carcinomas in contrast to mice expressing a functional PPARa (Hays et al., 2005; Peters et al., 1997a) . The observations that ligand-induced enhanced expression of cell cycle regulatory genes, hepatomegaly and replicative DNA synthesis do not occur in the absence of PPARa expression upon treatment with PPARa ligands (Hays et al., 2005; Peters et al., 1997a Peters et al., ,1998 , demonstrates that nonreceptor-dependent mechanisms do not contribute to the mechanisms underlying PPARa ligand-induced hepatocarcinogenesis. Unfortunately, null mouse models have not always been examined for PPAR ligand-induced toxicities, which in turn complicates interpretation of the literature on the mechanisms underlying PPAR ligand-induced toxicities. For many of the examples that will be discussed below, the precise series of molecular events that are initiated by administration of a PPAR ligand, and the physiological relevance to PPAR ligand-mediated events, including toxicity, are not always well characterized. This is due in part to the complexity associated with PPAR signaling on a number of different levels, and to the fact that there is a large diversity in the types of compounds that can act as either endogenous or exogenous PPAR ligands.
There are a variety of endogenous and exogenous compounds that can bind to and activate PPARs. However, the focus of this review is on PPAR ligands that are reported to cause toxicity, and will not include discussion on endogenous ligands since it is unlikely that under ordinary circumstances, activation by endogenous ligands leads to toxicity. Figure 2 illustrates a variety of different synthetic PPAR ligands. In some cases, specificity for a PPAR isoform is high but this is not always true. Synthetic compounds have recently been developed that exhibit high selectivity for one PPAR, as compared to the other two isoforms. For example, L796449 (a phenylacetic acid derivative) preferentially activates human PPARc as compared to PPARa or PPARb (Berger et al., 1999) ; GW501516, GW0742 and L165041 preferentially activate PPARb as compared to PPARa or PPARc (Berger et al., 1999; Sznaidman et al., 2003) ; and GW7647 preferentially activates PPARa as compared to PPARb or PPARc (Seimandi et al., 2005) . However, some compounds can activate all three PPARs (e.g., pan agonists) or in some cases, preferentially activate two of the three PPARs (e.g., dual agonists). For example, bezafibrate activates all three PPARs and the EC 50 for receptor activation is similar for all three PPARs ranging from 55-110 lM (Shearer and Hoekstra, 2003) . Muriglitazar, a recently developed dual PPARa/c agonist exhibits high selectivity for these PPAR isoforms with an EC 50 of 320 nM and 110 nM for PPARa and PPARc, respectively (Devasthale et al., 2005) . In addition to synthetic ligands for PPARs, endogenous compounds have also been shown to bind to and activate PPARs including fatty acids and eicosanoids (Forman et al., FIG. 2 . Chemical structure of representative PPAR ligands. Chemicals that activate PPARa include the fibrate class of hypolipidemic drugs such as clofibrate, bezafibrate, ciprofibrate, fenofibrate or Wy-14,643; phthalate monoesters such as monoethylhexyl phthalate; metabolites of trichloroethylene such as trichloroacetic acid and dichloroacetic acid; perfluorooctanoic acid and perfluoroctansulfonic acid; and the highly specific GW7647. Chemicals that activate PPARb/d include L-165041, GW501516, and GW0742. GW501516 is being developed as a drug to increase serum HDL cholesterol levels to improve dyslipidemias. Chemicals that activate PPARc include the anti-diabetic thiazolidinediones such as troglitazone, rosiglitazone, pioglitazone and ciglitazone and the non-thiazolidinedione L766499. It is important to note that in some cases, these chemicals have been shown to not only bind the receptor but also transactivate (e.g., L165041, GW7647, or L766499) while in other cases there is only evidence that the chemical can transactivate the receptor (e.g., TCA). In the latter case, it remains possible that the chemical displaces an endogenous ligand, which activates the receptor.
1997; Keller et al., 1993b; Kliewer et al., 1997; Yu et al., 1995) . Similar to synthetic PPAR ligands, endogenous compounds that activate PPARs exhibit variation in their specificity of activation.
The structure of the ligand binding domain of the PPARs determined using x-ray crystallography (Gampe et al., 2000; Nolte et al., 1998; Uppenberg et al., 1998; Willson et al., 2001; Xu et al., 1999 Xu et al., , 2001 Xu et al., , 2002 suggests that features of both the ligand and the receptor modulate relative ligand binding affinity. The acidic groups typically found in most PPAR ligands (Fig. 2 ) participate in hydrogen bonding within the ligand binding domain, in particular with a key tyrosine residue in the C-terminus AF-2 helix (Gampe et al., 2000; Nolte et al., 1998) . However, some PPARc ligands exhibit no binding to PPARb/d because the acidic head group is too large to fit into the ligand binding domain, which is significantly smaller as compared to the ligand binding domain of either PPARa or PPARc (Xu et al., 2001) . In contrast, GW501516 has an unsubstituted phenoxyacetic acid group that allows for a better fit into the ligand binding domain of PPARb/d. It was also been shown that tyrosine-314 in PPARa and the histidine-323 in PPARc are the primary reason for ligand specificity between these two receptors, as these amino acids facilitate critical hydrogen bonds within the ligand binding domain (Xu et al., 2001) . Thus, PPAR ligands activate PPARs due in part to specific functional groups within each molecule, in addition to structural differences in the amino acid composition of the ligand binding domain, that combined allow for hydrogen bonding and other molecular interactions between ligand and the receptor.
The review will focus on the different types of toxicity described in the literature to date for the different classes of PPAR ligands, with an emphasis on illustrating what is known regarding the role of the ligand/receptor-mediated mechanism, in addition to receptor-independent events that could contribute to toxicity (Table 1) . Some of this discussion centers on the use of null mouse models generated to determine receptorspecificity, which are described in detail elsewhere but summarized in Table 2 . Note. PPAR-null mouse models have been generated for all three isoforms. The PPARa-null mouse was the first and has been bred onto both the C57BL/6 and Sv/129 genetic background (Akiyama et al., 2001) . Disruption of the PPARc gene resulted in an embryonic lethal phenotype (Barak et al., 1999; Kubota et al., 1999; Rosen et al., 1999) . However, three different conditional PPARc-null mouse lines have subsequently been generated using LoxP/Cre technology. These mouse lines can be used to cross with various Cre transgenic mice to allow for tissue-specific and/or inducible deletion of PPARc to determine the requirement of this receptor for toxicity. There are two PPARb/d-null mouse models, one a conventional null model and the other a conditional model that utilizes the LoxP/Cre system for disrupting PPARb/d expression. These mice provide powerful genetic models that can be used for in vivo analysis or for obtaining cells for performing in vitro analysis.
PPARa LIGANDS
The focus of this review is on PPAR ligands that cause toxicity, with an emphasis on PPAR agonists with a reasonable number of reports to allow for a good discussion. It is noteworthy that there are relatively potent PPARa ligands that are under investigation as possible next generation hypolipidemic drugs but the toxicity (if any) associated with these recently developed chemicals is currently uncertain. Similarly, a number of PPARa/PPARc dual agonists are under development and in clinical trials. To date, the most well studied PPARa ligands are the fibrate class of hypolipidemic drugs (bezafibrate, clofibrate, fenofibrate, etc.) that have been used therapeutically for many years in humans. Fibrates, while relatively weak PPARa ligands, are capable of activating PPARa at pharmacological doses leading to increased expression of lipid metabolizing enzymes that effectively lower serum lipid levels in humans. Extensive studies have been performed examining the toxic effects of fibrates. Phthalates are another class of PPARa ligands (and in some cases PPARb/ d and PPARc ligands as well) that are used as monomers in the production of pliable plastic products such as footware, toys and hospital IV tubing and bags. Phthalates are not functional PPARa ligands until they are metabolized by carboxylesterases to phthalate monoesters, and the relative ability of phthalate monoesters to activate PPARa increases with increasing sidechain length of the esterified moiety (Bility et al., 2004) . Phthalate monoesters are very weak PPARa ligands as compared to fibrates and more potent synthetic PPARa ligands (Hurst and Waxman, 2003) . Trichloroacetic acid (TCA) and dicholoracetic acid (DCA), metabolites of trichloroethylene (TCE), an industrial solvent and environmental contaminant, can also activate PPARa although their affinities are among the lowest of all PPARa ligands (Maloney and Waxman, 1999) . Perfluoroalkyl acids and derivatives are also environmental contaminants that can activate PPARa (Maloney and Waxman, 1999; Shipley et al., 2004) . It is important to note that the relative ability to activate PPARa is typically based on cellbased reporter assays and in some cases relative binding assays that rely on ligand-induced structural changes in the receptor that result in coactivator and corepressor binding that can be assayed. However, ligand binding has not been demonstrated for many ligands, particularly low-affinity environmental and industrial chemicals. For example, while it is known that TCA and DCA can activate PPARa as shown by cell-based reporter assays (Maloney and Waxman, 1999) , it is not known whether these compounds directly bind to PPARa. It is possible that these, and other chemicals can ''activate'' PPARa, but do so by displacing other endogenous ligands, which in turn activate the receptor. They could also cause metabolic changes that lead to production of endogenous ligands, similar to the possibility that metabolites of ligands may be direct ligands for PPARa. These possibilities await futher experimentation. While there are no known toxicities associated with endogenous ligands of PPARa, there are a number of toxicities associated with the synthetic PPARa ligands in animal models.
Reproductive and Developmental Toxicity
Studies describing reproductive or developmental toxicity associated with exposure to PPARa ligands are limited. However, considerable research by pharmaceutical companies investigating the reproductive and developmental toxicities associated with the fibrate class of hypolipidemic drugs was likely performed prior to approval by the appropriate agencies. Administration of clofibrate or gemfibrozil to rats and mice during pregnancy causes atypical changes in maternal and fetal liver associated with peroxisome proliferation and induction of lipid catabolism (Cibelli et al., 1988; Stefanini et al., 1989; Wilson et al., 1991) , but evidence of overt teratogenesis is lacking (Chhabra and Kurup, 1978; Cibelli et al., 1988; Fitzgerald et al., 1987; Nyitray et al., 1980; Pantaleoni and Valeri, 1974) . High doses of clofibrate (>500 mg/kg) during pregnancy are reported to lead to an impaired incidence of successful implantation (Pantaleoni and Valeri, 1974) and reduced maternal weight gain (Cibelli et al., 1988) (which could be due to the induction of lipid catabolism). Thus, there is no strong evidence that either clofibrate or gemfibrozil can cause developmental toxicity/teratogenicity, while administration of clofibrate can cause some signs of maternal toxicity, but the dose required to elicit this response is considerably higher than those used therapeutically.
While administration of fibrates during pregnancy is not associated with teratogenicity, there are numerous reports that some environmental contaminants including phthalates, perfluoroalkyl derivatives and TCE, which are relatively weak PPARa agonists, can cause both reproductive and developmental toxicity. Administration of phthalates, prior to and during pregnancy, in rodent models can cause reduced fertility rates (Peters and Cook, 1973; Singh et al., 1974; Tyl et al., 1988) , altered ovulation (Davis et al., 1994) , altered development of the male reproductive tract and impaired spermatogenesis (reviewed in Corton and Lapinskas, 2005) and teratogenesis including skeletal, cardiac, and neural tube defects (Gao et al., 2003; Ritter et al., 1985; Shiota and Nishimura, 1982; Singh et al., 1972; Tomita et al., 1982) . Exposure to perfluorooctanoic acid (PFOA) or perfluorooctane sulfonate (PFOS) during pregnancy can cause developmental defects including reduced fetal weights, skeletal and cardiac malformations (reviewed in Lau et al., 2004) . In contrast, exposure to TCE during pregnancy is associated with cardiac defects (Dawson et al., 1990 (Dawson et al., , 1993 Loeber et al., 1988) but not with changes in fertility, ovulation, or testicular function.
The role of PPARa in mediating the developmental and reproductive toxicity associated with exposure to the relatively weak PPARa ligands, phthalates, PFOA, PFOS, or TCE is not clear. Since administration of fibrates during pregnancy does not result in overt teratogenesis while exposure to the relatively weak PPARa ligands does, this argues against the hypothesis that activation of PPARa during development is a central mechanism of action leading to teratogenesis. Consistent with this view, administration of DEHP during organogenesis causes neural tube defects in both wild-type and PPARa-null mice (Peters et al., 1997c) , demonstrating that PPARa is not required to mediate this effect. Indeed, there is good evidence that DEHP and other phthalates may cause a functional zinc deficiency, which could explain some of the developmental and/or reproductive alterations induced by phthalate exposure by a mechanism independent of PPARa Parkhie et al., 1982; Peters et al., 1997c; Thomas et al., 1982) . While cardiac malformations are not reported with fibrate exposure during development, it is of interest to note that they are found after exposure to phthalates, PFOA, PFOS, and TCE. However, administration of both clofibrate and PFOS, but not PFOA, during gestation results in significant perinatal mortality Lau et al., 2003; Nyitray et al., 1980) . Whether or not PPARa mediates either of these effects has not been examined to date. The observations that clofibrate, gemfibrozil, PFOA exposures do not cause altered ovulation while phthalate esters do, argues against the notion that activation of PPARa is a central mechanism leading to altered female reproductive toxicity. It has been hypothesized that activation of PPARa leads to inhibition of aromatase and increased expression of 17b-HSD IV, which combined could contribute to reduced estradiol levels and anovulation (Lovekamp-Swan and Davis, 2003) . However, mechanistic studies demonstrating a direct role of PPARa in modulating expression of these gene products are lacking. In contrast, ligand activation of PPARa was found to increase, rather than inhibit, aromatase expression (Liu et al., 1996a,b) , and administration of DEHP actually increases serum estradiol in vivo (Eagon et al., 1994) . In males, there is good evidence that PPARa mediates phthalate-induced reproductive toxicity as DEHP exposure causes testicular toxicity and impaired spermatogenesis in wild-type mice, but not in similarly treated PPARa-null mice (Ward et al., 1998) . However, PPARa-null mice maintained on a DEHP diet after all wild-type mice had died, also exhibit signs of testicular toxicity including tubule lesions and diffuse tubular aspermatogenesis (Ward et al., 1998) . This suggests that DEHP can also lead to male reproductive toxicity through mechanisms that do not require the PPARa. This also emphasizes the need for animal models that do not exhibit PPARa-induced liver toxicities so that extrahepatic toxicities can be examined after long periods of ligand exposure that would otherwise cause morbidity and mortalities due to hepatocarcinomas (see below).
Collectively, these studies indicate that ligand activation of PPARa is not likely a general mechanism of action leading to developmental toxicity. However, it is still possible that some weak PPARa ligands could cause developmental defects by activating PPARa. Many questions remain regarding the role of PPARa in development, and whether or not this receptor mediates developmental/reproductive toxicity induced by some environmental toxicants, whether there are species differences in the responses resulting from exposure to these chemicals, and whether the environmental concentrations are capable of activating the receptor.
Hepatotoxicity
The most classic hallmark of liver toxicity induced by activation of PPARa is hepatocarcinogenesis. However, this subject has been extensively reviewed and will not be considered in detail. It is worth noting though, that numerous studies examining hepatocarcinogenesis caused by ligand activation of PPARa provide excellent examples demonstrating receptor-specificity, species differences in receptor activity, and relative ligand binding/activation, which are critical factors that mechanistically influence this ligand/receptor-mediated effect (reviewed in Klaunig et al., 2003; Peters et al., 2005) . Other than the pleiotropic response associated with PPARa ligand-induced liver cancer (peroxisome proliferation, increased hepatocellular proliferation, hepatomegaly, increased expression of numerous target genes, etc.), there is little evidence suggesting that PPARa ligands are hepatotoxicants. No increases in serum levels of alanine aminotransferase or aspartate aminotransferase are observed in rats treated with clofibrate (Tanaka et al., 1992) , and humans treated with fenofibrate only exhibit marginal increases (<3-fold) in these markers of liver toxicity (Balfour et al., 1990) .
In contrast to the well-documented hepatocarcinogenic effect of PPARa ligands, there is also evidence that PPARa ligands can be used to prevent liver toxicity. Treatment of ethanol-fed mice with a PPARa agonist can reverse ethanolinduced fatty liver despite continued ethanol consumption (You and Crabb, 2004) , and PPARa-null mice exhibit exacerbated fatty liver and symptoms of cirrhosis in response to chronic ethanol consumption . Activation of PPARa also influences acute liver toxicity. Pre-treating mice or hepatocytes with PPARa ligands can prevent acute hepatotoxicity induced by acetaminophen, bromobenzene, carbon tetrachloride, and chloroform Manautou et al., 1994 Manautou et al., , 1998 Nicholls-Grzemski et al., 1992; Shankar et al., 2003) . That this protective effect of PPARa ligands against acute liver damage requires the receptor was demonstrated by studies showing the lack of protection in PPARa-null mice Chen et al., 2000; Shankar et al., 2003) . Interestingly, caloric restriction can protect against thioacetamide-induced liver toxicity, and this effect requires PPARa as exacerbated liver toxicity is found in similarly treated PPARa-null mice . These findings suggest that although chronic ligand activation of PPARa in liver can lead to hepatocarcinogenesis in rodents, paradoxically, ligand activation can also prevent acute liver damage by alcohol and environmental liver toxicants. The protective effect TOXICOLOGY OF PPAR LIGANDS of PPARa ligand activation in liver is likely the result of receptor-mediated induction of fatty acid catabolism and/or through anti-inflammatory/antioxidant activity associated with PPARa ligands, which could significantly reduce the ability of these agents (ethanol, carbon tetrachloride, etc.) to induce steatosis and related liver toxicity.
Recent findings also suggest that activation of PPARa may modulate liver toxicity by interfering with aryl hydrocarbon receptor (AhR)-dependent signaling. Expression of CYP1A2 mRNA and enzyme activity in liver are both decreased in rats treated with ciprofibrate (Gallagher et al., 1995) . Similarly, decreased expression of CYP1A1 and CYP1A2 mRNA and protein is found rat liver after clofibrate treatment, and this effect appears to be due to reduced turnover of the AhR that mediates induction of CYP1A1 and CYP1A2 (Shaban et al., 2004) . These combined observations suggest that PPARa ligands could potentially inhibit bioactivation and/or detoxification of chemical carcinogens/toxicants catalyzed by CYPs through mechanisms that are not clearly defined. However, another recent report suggests that PPARa ligands can induce CYP1A1. Increased mRNA encoding CYP1A1 is found in CaCo2, HepG2, and human keratinocytes in response to 200 lM Wy-14,643, and this increase parallels increased EROD activity observed in CaCo2 cells treated with Wy-14,643 (Seree et al., 2004) . These findings suggest that there could be a species difference in the effect of PPARa ligands on the expression of CYP1A1; PPARa ligands inhibit CYP1A1/ CYP1A2 expression in rats whereas PPARa ligands induce expression of CYP1A1 in human cell lines. Further work is necessary to determine whether PPARa ligand-induced changes in CYP1A1/CYP1A2 expression modulate bioactivation and/ or detoxification of chemical toxicants/carcinogens.
Lastly, fibrate therapy is also associated with cholelithiasis (gallstones). Humans treated with clofibrate, bezafibrate, or fenofibrate have a significantly increased incidence of cholelithiasis (Bateson et al., 1978; Caroli-Bosc et al., 2001; Mazzella et al., 1990; Raedsch et al., 1995) . Increased cholelithiasis is not consistently observed with all PPARa ligands as etofibrate and gemfibrozil treatment are not as lithogenic as compared to bezafibrate or clofibrate, respectively (Mazzella et al., 1990; Raedsch et al., 1995) . One mechanism that may underlie the increased incidence of cholelithiasis is that fibrates can increase the lithogenicity of bile acids, due to increased biliary output of cholesterol and reduced output of bile acids, which can be measured clinically by the cholesterol saturation index (Carey, 1978) . Bezafibrate, fenofibrate, and ciprofibrate all increase the cholesterol saturation index indicative of increased lithogenicity (Angelin et al., 1979; Leiss et al., 1986; Palmer, 1985) . The possibility that the increased lithogenicity of bile that leads to increased cholelithiasis is mediated by PPARa is suggested by the finding that reduced bile output by ciprofibrate and bezafibrate requires a functional PPARa in mice (Hays et al., 2005; Post et al., 2001) . However, since the relative ability of different PPARa ligands to cause cholelithiasis varies, other mechanisms contributing to this effect cannot be excluded.
Muscle Toxicity
Fibrate administration can cause myopathy in humans, and in rare cases lead to rhabdomyolysis. Myopathies and/or rhabdomyolysis have been reported to occur in patients treated with clofibrate (Bridgman et al., 1972; Langer and Levy, 1968; Rush et al., 1986) , fenofibrate (Alsheikh- Ali et al., 2004; Barker et al., 2003; Blane and Pinaroli, 1980; Clouatre et al., 1999) , bezafibrate (Gorriz et al., 1995; Heidemann and Bock, 1981; Kanterewicz et al., 1992; Rumpf et al., 1984; Vita et al., 1993) , ciprofibrate (Bourrier et al., 1990; Delangre et al., 1990) , and gemfibrozil (Bermingham et al., 2000; Chow and Chow, 1994; Layne et al., 2004; Magarian et al., 1991; Zimetbaum et al., 1991) . The mechanisms underlying fibrateinduced myopathy or rhabdomyolysis are uncertain. There is some evidence that the mechanism involves the relative concentration of the drug in blood, since there are notable differences in the relative incidence of this toxicity induced by different fibrates and the fact that myopathy is more common in patients with kidney failure or hypoalbuminemia (Hodel, 2002) . This toxicity in humans underscores the efforts to develop new high affinity ligands for PPARa. It is of interest to note that increased expression of lipoprotein lipase in skeletal muscle leads to severe myopathy in mice (Levak-Frank et al., 1995) , since lipoprotein lipase is a known PPARa target gene (Heller and Harvengt, 1983; Schoonjans et al., 1996) . Whether or not PPARa is required to mediate myopathy or rhabdomyolysis has not been examined to date.
Extra-hepatic Carcinogenesis
In addition to the well-described role of PPARa ligands in causing hepatocellular carcinomas in rodents, PPARa ligands have also been linked to other malignancies. The ''Tumor Triad'' has been described in rats treated with PPARa ligands since they result in liver cancer, Leydig cell tumors, and pancreatic acinar cell tumors. However, only nine of fifteen PPARa ligands examined to date (clofibrate, DEHP, HCFC-123, fenofibrate, gemfibrozil, methylclofenapate, PFOA, tibric acid, and Wy-14,643) result in the Tumor Triad, while the other six (cinnamyl anthranilate, nafenopin, butyl benzyl phthalate, DINP, perchloroethylene, and trichloroethylene) only result in a subset of carcinogenic endpoints (e.g., liver cancer and pancreatic acinar cell tumors but not Leydig cell tumors, etc.) (reviewed in Klaunig et al., 2003) . Additionally, Leydig cell tumors and pancreatic acinar cell tumors have only been reported to occur in rats, and have not been observed in mice; although the number of chemicals examined in mice to date is less as compared to those examined in rats (reviewed in Klaunig et al., 2003) . Hypothetical mechanisms have been postulated that could mediate PPARa ligand-induced Leydig cell and pancreatic acinar cell tumors via a PPARa-dependent pathway, but this has not been clearly demonstrated to date. If PPARa were required to mediate PPARa ligand-induced Leydig cell and/or pancreatic acinar cell tumors, this would suggest that there could also be a species difference between rats and mice since mice appear to be refractory to these effects.
Ligand activation of PPARa can protect against cisplatininduced acute renal failure. There are a number of molecular events that could contribute to this protection including induction of fatty acid oxidation (Li et al., 2004b) , repression of endonuclease G that leads to reduced apoptosis and necrosis (Li et al., 2004a) , and anti-inflammatory activities of Wy-14,643 (Li et al., 2005b) . That these effects are receptor-dependent was demonstrated by the use of PPARa-null mice, which are not protected from cisplatin-induced acute renal failure after administration of PPARa ligands.
There is one report suggesting that PPARa ligands may potentiate breast cancer cell proliferation as well. Wy-14,643 and clofibrate treatment increases the growth of human breast cancer cell lines (Suchanek et al., 2002) . Whether or not this effect is mediated by PPARa and/or other receptor-independent mechanisms has not been determined to date.
In many cases, it has not been established whether hepatic PPARa is responsible for non-hepatic toxicity and carcinogenicity. The severe hepatomegaly and carcinogenicity found in rats and mice could affect other tissues. This is especially noteworthy, since humans do not exhibit the liver toxicities found with the rodent models treated with PPARa ligands. It is thus important to find suitable animal models to predict potential toxicities in humans. Ideally, a liver-specific PPARa-null mouse could be used for this purpose but to date, this model has not been available. However, a PPARa-humanized mouse was recently produced that does not exhibit the liver toxicities found in wild-type mice that might be of value in determining off-target toxicities of PPARa ligands (Cheung et al., 2004) .
PPARc LIGANDS
Thiazolidinediones are the most widely studied PPARc ligands, and were found to improve insulin sensitivity in diabetic animals more than ten years before PPARc was cloned. Troglitazone (Rezulin) was the first drug approved for this use, followed by rosiglitazone (Avandia) and pioglitazone (Actos). The mechanism of action of thiazolidinediones was not known until 1995 when Lehmann et al. reported that thiazolidinediones were high affinity ligands for PPARc (Lehmann et al., 1995) . Endogenous ligands for PPARc have also been described (e.g., 15deoxyD
12,14 prostaglandin J 2 , 15D-PGJ 2 ), and additional synthetic ligands for the receptor are under development. However, acute liver toxicity found in patients prescribed troglitazone led to the withdrawal of Rezulin from the market along with peaked concerns about the safety of PPARc activators. Phthalate monoesters are known to activate PPARa, but recent findings demonstrate that this class of chemicals can also activate PPARc (Bility et al., 2004; Hurst and Waxman, 2003) . To date, it has not been clearly established whether PPARc mediates any of the toxicities associated with PPARc ligands. Surprisingly, while PPARc ligands can significantly improve insulin sensitivity and PPARc is required to mediate this effect, the precise mechanisms leading to improved insulin sensitivity are uncertain (Knouff and Auwerx, 2004; Rangwala and Lazar, 2004) . PPARc, while abundantly expressed in adipose tissue, is not highly expressed in skeletal muscle and is almost absent in normal liver, tissues where appreciable alterations in glucose transport and fatty acid metabolism are found after treatment with PPARc ligands, suggesting that PPARc ligands mediate their effects by secondary changes induced by PPARc activity in adipose tissue such as production of adipokines such as leptin, resistin, and adiponectin (Bouskila et al., 2005) . Whether or not this type of regulation also influences PPARc ligand-induced toxicities is unknown.
Reproductive and Developmental Toxicity
It is of interest to note that there is strong evidence that PPARc is required for development since targeted disruption of this gene results in embryo lethality, due in part to defective placental development (Barak et al., 1999; Kubota et al., 1999; Rosen et al., 1999) . This demonstrates that the receptor itself is essential for developmental processes, and suggests that ligand activation during development could influence specific molecular events modulated by PPARc. There are limited published reports describing the outcome of developmental or reproductive toxicity testing for specific PPARc ligands. However, rosiglitazone and pioglitazone are classified as category B drugs for use during pregnancy since animal studies have shown no evidence of altered development and limited analysis in humans are consistent with these findings (Kalyoncu et al., 2005; Yaris et al., 2004) . It has been hypothesized that phthalate monoesters can lead to anovulation by activating PPARc leading to inhibition of aromatase expression (Lovekamp-Swan and Davis, 2003) , a mechanism that has also been linked to activation of PPARa as described above. By contrast, the more specific PPARc ligand troglitazone has been shown to improve ovulation in humans with polycystic ovary syndrome (Azziz et al., 2001; Mitwally et al., 1999) , suggesting that ligand activation of PPARc leads to changes that facilitate ovulation rather than inhibit this process. The mechanisms underlying these effects have not been defined, and it is currently unclear whether PPARc is required to mediate these effects or whether there are species differences between these responses. PPARc may also regulate trophoblast differentiation, as troglitazone exposure leads to differentiation of human trophoblasts (Schaiff et al., 2000) , and this may be mediated by PPARc-dependent regulation of mucin expression (Shalom- Barak et al., 2004) . Interestingly, the ''natural'' PPARc ligand 15D-PGJ 2 diminishes trophoblast differentiation, suggesting that there could TOXICOLOGY OF PPAR LIGANDS be ligand-specific effects. Whether this is due to differential recruitment of co-effectors (e.g., histone acetyltransferases, histone deacetylases, etc.) has not been determined to date. Further, whether exogenous ligand activation of PPARc during placental development impairs embryo or fetal development has not been reported in the literature to date.
Hepatotoxicity
One of the most studied toxic effects of a PPARc agonist is hepatotoxicity. Early clinical trails with troglitazone indicated elevations in serum alanine aminotransferase (ALT) of greater than three times the upper normal range in 1.9% of 2510 of treated patients (Watkins and Whitcomb, 1998) . Subsequent case reports demonstrated liver toxicity in humans treated with troglitazone (Gitlin et al., 1998; Herrine and Choudhary, 1999; Neuschwander-Tetri et al., 1998) . Additionally, two case reports suggest that liver toxicity may occur with rosiglitazone, although clinical trials examining hepatotoxicity demonstrated similar low incidence of elevated ALT levels (Al-Salman et al., 2000; Forman et al., 2000) . The mechanism of PPARc ligandinduced liver toxicity is poorly understood. Since troglitazone induces CYP3A4 (Dimaraki and Jaffe, 2003; Ramachandran et al., 1999) , it has been hypothesized that potentially toxic quinones derived from CYP3A4-dependent metabolism could cause liver damage (Neuschwander-Tetri et al., 1998; Yamamoto et al., 2002) . Since clinical trials demonstrate a large difference in the ability of troglitazone to cause liver toxicity versus rosiglitazone or pioglitazone (Al-Salman et al., 2000; Watkins and Whitcomb, 1998) , the hepatotoxicity may result from genetic differences in the population in the induction of CYP3A4 or the metabolic activation of troglitazone that results in these rare cases of hypersensitivity. It should also be noted that under normal circumstances, PPARc is not expressed to any appreciable degree in normal liver; however, it is expressed at functionally significant levels in steatotic livers (Matsusue et al., 2003) . Thus, it cannot be ruled out that hepatotoxicity may be the result of abnormal target gene expression in patients with fatty livers. Surprisingly, while PPARc ligands can cause liver toxicity, recent findings suggest that PPARc ligands can protect against liver damage. Thiazolidinedione administration improves the histological features of nonalcoholic steatohepatitis and restores serum ALT levels in patients with nonalcoholic steatohepatitis (Caldwell et al., 2001; Neuschwander-Tetri et al., 2003) . Pioglitazone can also prevent carbon tetrachloride-induced fibrosis (Kon et al., 2002) , and acute liver toxicity from ethanol and lipopolysaccharide exposure (Ohata et al., 2004) . One mechanism that may contribute to the protective effect of PPARc ligands against liver toxicity, in particular fibrogenesis, is inhibition of stellate cell activation. PPARc ligands can inhibit stellate cell activation, including suppressing expression of collagen and smooth muscle actin, and these effects appear to require PPARc as they do not occur in the presence of a PPARc antagonist (Miyahara et al., 2000) . Given the paradoxical observations that PPARc ligands may cause hepatotoxicity and yet protect against chemical-induced liver toxicity, this demonstrates that the mechanisms underlying the effects of PPARc ligands in liver are largely unknown. Examination of liver cell-specific PPARc-null mice could be useful for delineating the role of PPARc in liver.
Cardiac Toxicity
The effect of PPARc ligands on heart function is somewhat controversial. Thiazolidinediones cause cardiac hypertrophy and administration of a number of different thiazolidinediones including rosiglitazone to F344 rats causes a significant increase in heart weight (Oguchi et al., 2000) . Deleting PPARc expression in cardiomyocytes demonstrates that cardiac hypertrophy does not always require PPARc expression in these cells, as hypertrophy (albeit somewhat different) was observed in both wild-type and cardiac myocyte-specific PPARc-null mice (Duan et al., 2005) . In other models, PPARc ligands inhibit cardiac myocyte hypertrophy (Asakawa et al., 2002; Yamamoto et al., 2001) , which is consistent with the ability of PPARc to interfere with NF-jB signaling (Wang et al., 2002) . Since congestive heart failure can be negatively influenced by cardiac hypertrophy, these opposing findings suggest that PPARc ligands may or may not be of benefit to diabetics using thiazolidinediones, as diabetics are at particularly high risk for congestive heart failure. The specific mechanism mediating changes in cardiac myocyte hypertrophy has not been elucidated, but could involve PPARc/NF-jB signaling. There is also evidence that PPARc ligands increase the incidence of heart failure in type II diabetics (Delea et al., 2003) . Thus, there is current concern regarding the administration of PPARc ligands to type II diabetics because they are known to cause peripheral edema, which could exacerbate congestive heart failure (Nikolaidis and Levine, 2004) . Several mechanisms have been postulated that could lead to PPARc ligand induced edema, which in turn contributes to cardiac toxicity. For example, PPARc ligands have calcium channel blocking activity that may or may not be receptor-dependent (Song et al., 1997; Zhang et al., 1994) . However, recent work strongly suggests that the edema resulting from PPARc ligands is mediated by a receptor-dependent mechanism. Deleting PPARc from the collecting duct of the nephron eliminates PPARc ligandinduced weight gain due to water accumulation (Guan et al., 2005b; Zhang et al., 2005) , and this effect appears to be mediated by PPARc-dependent regulation of epithelial sodium channel expression (Guan et al., 2005b) . This suggests that PPARc-dependent regulation of critical regulatory proteins in the kidney secondarily influences fluid retention that modulates cardiac function. It will be of great interest to determine whether PPARc ligand-induced edema is altered in individuals with mutations in PPARc (Barroso et al., 1999; Gurnell et al., 2000) or splice variants of PPARc (Sabatino et al., 2005) .
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Carcinogenesis
The effect of PPARc ligands on carcinogenesis is controversial. There are a number of studies suggesting that ligand activation of PPARc can potentiate tumorigenesis (Table 3) . However, it is unknown if the mechanisms mediating these effects are receptor-dependent or -independent pathways, or whether there are species differences as suggested by the longterm troglitazone bioassay (Heaney et al., 2002) , and/or whether they are due to ligand-specific effects. Further complicating this issue is the larger body of evidence that PPARc ligands induce differentiation, inhibit cell growth, induce apoptosis and/or inhibit tumorigenesis in a variety of cancer models (Table 3 ). Similar to the uncertainty associated with the mechanisms that potentiate tumorigenesis by PPARc ligands, the mechanisms leading to attenuation of carcinogenesis by PPARc ligands are unclear. While it is known that PPARc ligands can induce differentiation, inhibit cell growth, induce apoptosis and/or inhibit tumorigenesis in a variety of cancers, there is only limited evidence that these effects are mediated by both receptor-dependent and receptor-independent mechanisms. For example, the use of null mice to demonstrate the requirement of chemopreventive activity of PPARc ligands is lacking for the most of these models. However, heterozygous PPARc-null mice have been used to demonstrate that PPARc is required to mediate inhibition of gastric cancer in a mouse model (Lu et al., 2005) . This mouse model has also been used Note. This table is a summary of studies examining the effect of different PPARc ligands on cancer-related endpoints. a Potentiates is defined as effects ranging from increased incidence of tumors, increased tumor cell growth, inhibition of apoptosis, or increased angiogenic factors. b No effect indicates references where ligand administration had no effect on these tumor types.
c Inhibition is defined as effects ranging from decreased incidence of tumors, decreased tumor cell growth, increased apoptosis, increased differentiation, or inhibition of cell proliferation.
*Only observed in mice treated with a high dose, but not in rats. **Only observed in female mice treated with a high dose, but not in male mice or rats.
TOXICOLOGY OF PPAR LIGANDS
to demonstrate a potential tumor suppressive effect of PPARc in azoxymethane-induced colon cancer (Girnun et al., 2002) and in 7,12-dimethylbenz[a]anthracene-induced mammary and skin cancer . The link between PPARc and carcinogenesis has not been established but clues are beginning to emerge. In colon, b-catenin expression, known to be involved in colon carcinogenesis, is enhanced in PPARc heterozygous mice (Girnun et al., 2002) . Expression of mRNA encoding differentiation-related target genes (keratin 19, keratin 20 and Kruppel-like factor 4 [KLF4]) that is induced by PPARc ligands in colonic epithelium is significantly lower in PPARc heterozygotes (Drori et al., 2005) . This suggests that PPARc mediates the induction of differentiation-related target genes by binding to PPREs and modulating transcription as previously described (Fig. 1A) . There is also evidence that the induction of KLF4 by PPARc ligands may require PPARc, but is also mediated by the MEK/ERK pathway in colon cancer cells (Chen and Tseng, 2005) . It also remains a possibility that the anti-inflammatory effects of PPARc ligand could be involved in suppression of carcinogenesis (Ricote et al., 1998a (Ricote et al., ,b, 1999 . Indeed, cytokine expression is known to enhance chemical-induced colon and liver carcinogenesis (Greten et al., 2004; Karin, 2005; Karin and Greten, 2005; Maeda et al., 2005) . Another potential mechanism for tumor suppression by PPARc is suppression of cyclin D1 expression. PPARc ligands were found to markedly suppress expression of cyclin D1 in a colon cancer cell line (Chen and Xu, 2005) , breast cancer cells (Huang et al., 2005) , an immortalized hepatocyte cell line and in normal skin keratinocytes . However, controversy exists whether the effect is directly mediated by PPARc. Conversely, cyclin D1 was shown to inhibit stimulation of adipogenesis by PPARc through enhanced recruitment of histone deacetylase to the PPARc promoter (Fu et al., 2005) . Other studies have also shown that inhibition of cell proliferation caused by PPARc ligands are due in part to PPARc-independent molecular events. For example, inhibition of replicative DNA synthesis by troglitazone occurs in both wild-type and PPARc-null ES cells, and this inhibition could be mediated by PPARc-independent inhibition of translation initiation (Palakurthi et al., 2001) . Troglitazone, but not other PPARc ligands, increases early growth response 1 (EGR1), which leads to apoptosis, through an ERK-dependent mechanism that does not require PPARc (Padilla et al., 2000b) . Troglitazone can also inhibit cell proliferation by reducing intracellular pH, independent of PPARc (Turturro et al., 2004) . The extensive analysis that has been performed to date examining the mechanisms underlying the chemopreventive properties associated with PPARc ligands provide excellent examples demonstrating that the effects induced by PPARc ligands are not mediated solely by the receptor and occur by other mechanisms including activation of intracellular kinases and other ''off-target'' modes of action (Fig. 1) .
PPARb/d LIGANDS
While extensive studies have been focused on examining the effects of PPARa and PPARc ligands, comparably fewer studies have been published on the effects of PPARb/d ligands. It was not until recent years that highly specific ligands for PPARb/d were described, and thus toxicities associated specifically with PPARb/d ligands are not as well characterized as compared to those for PPARa and PPARc ligands. L-165041 was one of the first high affinity ligands for PPARb/d described in the literature (Berger et al., 1999) , followed by GW501516 (also referred to as GW1516) and GW610742 (also referred to as GW0742) (Sznaidman et al., 2003) . Treatment of obese nonhuman primates with GW501516 results in normalization of metabolic parameters and reduction of fatty adiposity (Oliver et al., 2001) , which may be related to the ability of PPARb/d ligands to increase serum HDL levels (Leibowitz et al., 2000; Oliver et al., 2001; Wallace et al., 2005) . Activation of the PPARb/d promotes fatty acid catabolism in skeletal muscle by up-regulation of fatty acid uptake, b-oxidation and energy uncoupling (Holst et al., 2003a,b; Luquet et al., 2004; Tanaka et al., 2003; Wang et al., 2003) . Studies with PPARb/d-null mice have revealed a role for PPARb/d in control of VLDL levels Chawla et al., 2003) . PPARb/d may also be involved in the metabolic responses of skeletal muscle to environmental changes, such as long-term fasting or physical exercise, by controlling the number of oxidative myofibers . These observations strongly suggest that PPARb/d agonists may have therapeutic applications for the treatment of metabolic syndrome, obesity and low HDL levels.
Reproductive and Developmental Toxicity
The ability of teratogenic derivatives of valproic acid to induce differentiation and activate PPARb/d suggests that PPARb/d may be involved in mechanisms underlying valproic acid-induced developmental toxicity (Lampen et al., 1999) , which includes neural tube defects. This is of interest because PPARb/d mRNA is expressed at high levels during neural tube development (Braissant and Wahli, 1998) . Since non-teratogenic derivatives of valproic acid do not induce differentiation of F9 teratocarcinoma cells or activate PPARb/d reporter constructs, while teratogenic derivates of valproic acid do (Lampen et al., 1999; Werling et al., 2001) , this suggests that valproic acid could cause altered differentiation during neural tube development leading to neural tube defects. Stably transfected F9 teratocarcinoma cell lines expressing a PPARb/d antisense RNA vector do not exhibit increased expression of activating protein-2 (AP2, a marker of differentiation) in response to valproic acid (Werling et al., 2001) , suggesting that PPARb/d is required to mediate valproic acid-induced differentiation of F9 teratocarcinoma cells. However, valproic acid does not bind to PPARb/d/RXRa heterodimers (Lampen et al., 2001) , indicating that while PPARb/d appears to be required for valproic acid induced differentiation of F9 teratocarcinoma cells, its direct role in mediating valproic acid teratogenicity remains uncertain. Further, teratogenic derivatives of valproic acid induce expression of neural cell adhesion molecule (NCAM) and polysialyltransferases (PST), non-teratogenic derivatives of valproic acid do not, and expression of a dominant negative PPARb/d construct prevents increased expression of NCAM by valproic acid (Lampen et al., 2005) . It is surprising that carbaprostacyclin (a known PPARb/d ligand) did not induce NCAM expression (Lampen et al., 2005) . While there is evidence suggesting that PPARb/d is required to mediate valproic acid-induced differentiation of F9 teratocarcinoma cells, valproic acid does not bind directly to PPARb/d/RXRa heterodimers (Lampen et al., 2001) . This suggests that differentiation of F9 teratocarcinoma cells and induction of NCAM and PST, two endpoints that both correlate well with activation of PPARb/d, are not directly mediated by a classic ligand-receptor mediated mechanism by altering changes in gene expression (Fig. 1A) . Combined, while there is evidence suggesting that PPARb/d could modulate developmental toxicity resulting from valproic acid exposure during pregnancy, the specific mechanism(s) underlying this effect remains uncertain.
Phthalate monoesters can also activate PPARb/d (Bility et al., 2004; Lampen et al., 2003) , which indirectly suggests that developmental and/or reproductive toxicity resulting from exposure to these chemicals, could also be influenced by PPARb/d. However, this possibility has not been critically examined to date.
Hepatotoxicity
PPARb/d has recently been implicated in hepatic stellate cell (HSC) proliferation and liver fibrosis. Hepatic stellate cells become activated in response to liver toxicants, leading to deposition of extracellular matrix and fibrosis (Sato et al., 2003) . In addition to hepatic Kupffer cells, stellate cells are also involved in regulating the inflammatory response in liver by modulating growth factor and cytokine expression (Sato et al., 2003) . Stellate cells are best characterized as cells that contain a significant amount of vitamin A. Once activated, stellate cells release the stored vitamin A, proliferate and increase expression of extracellular matrix proteins including collagen and smooth muscle actin (Sato et al., 2003) . Interestingly, stellate cells spontaneously become activated when cultured in vitro as shown by increased proliferation and expression of extracellular matrix proteins (Sato et al., 2003) . It was recently shown that cultured hepatic stellate cells that become activated in vitro express high levels of mRNA encoding PPARb/d by day seven of culture, but expression decreases between days fourteen and twenty-eight of culture (Hellemans et al., 2003b) . Ligand activation of PPARb/d by L-165041 marginally enhanced hepatic stellate cell proliferation and increased the synthesis of genes associated with the extracellular matrix (Hellemans et al., 2003a) . Co-treatment of L-165041 with the liver toxicant carbon tetrachloride resulted in enhanced expression of extracellular matrix proteins (Hellemans et al., 2003a) . Expression of an antisense PPARb/d construct results in a diminished proliferative response after treatment of cultured hepatic stellate cells with L-165041 (Hellemans et al., 2003a) . Collectively, these data suggest that PPARb/d potentiates hepatotoxicity, and that endogenous ligands for PPARb/d could modulate hepatotoxicity by activating PPARb/d, which then regulates the ensuing responses leading to fibrosis. This hypothesis has not been examined in vivo using PPARb/d-null mice to date. It is worth noting that this putative role for PPARb/d in hepatotoxicity is in direct contrast to a protective role of ligand activation of PPARc in hepatotoxicity where it has been shown that PPARc ligands can inhibit stellate cell activation and likely protect against liver toxicity (Hazra et al., 2004; Miyahara et al., 2000) .
Cardiac Toxicity
In contrast to PPARc ligands where some controversy exists, administration of PPARb/d ligands is thought to be protective against cardiomyopathy. Cardiomyocyte-specific deletion of PPARb/d in mice causes cardiac dysfunction, progressive myocardial lipid accumulation, cardiac hypertrophy and congestive heart failure with reduced survival (Cheng et al., 2004) . This is thought to be due to PPARb/d-dependent regulation of fatty acid oxidation genes and decreased basal myocardial fatty acid oxidation. In cultured neonatal rat cardiomyocytes, the PPARb/d activator L-165041 inhibits phenylephrine (PE)-induced protein synthesis, induction of the fetal-type gene atrial natriuretic factor (ANF) and cardiac myocyte size (Planavila et al., 2005) . The induction of monocyte chemoattractant protein-1 by NF-jB in cardiac myocytes is also reduced with treatment of L-65041. Combined, these data suggest that PPARb/d activation inhibits PE-induced cardiac hyptertrophy by inhibiting NF-jB activation (Planavila et al., 2005) .
Carcinogenesis
The role of PPARb/d in carcinogenesis is controversial since there is evidence that ligands for PPARb/d may potentiate or attenuate epithelial cancers of the colon and skin. A recent review provides a more in depth discussion of this subject that will only be briefly described here (Burdick et al., 2005) . The first evidence suggesting that PPARb/d potentiates colon cancer was the observation that the adenoma polyposis colitis (APC) tumor suppressor gene negatively regulates PPARb/d expression in colorectal tumor cell lines (He et al., 1999) . Disruption of the APC gene reduces inhibition of b-catenin/ TCF-4 complexes, leading to upregulation of the oncongenes c-myc and cyclin D1 and dysregulated growth of cancer cells in the colon (He et al., 1999) . Based in part on these studies, it was hypothesized that COX-derived metabolites could serve as PPARb/d ligands to increase signaling for cell proliferation and TOXICOLOGY OF PPAR LIGANDS that this mechanism could explain the known chemopreventive effects of COX inhibitors. A number of subsequent studies support this model. PPARb/d expression is higher in colorectal tumors compared to normal tissue and this increase in expression correlates with increased expression of COX-2 in colon cancer in humans and a rodent model of colon cancer (Gupta et al., 2000) . Over-expression of COX2 and PGI synthase in an osteocarcinoma cell line reportedly increases PPARb/d trans-activation (Gupta et al., 2000) . Additionally, colorectal tumor cell lines lacking PPARb/d expression exhibit decreased growth of xenografts (Park et al., 2001) and treating APC min mice with the PPARb/d ligand GW1516 leads to enhanced small intestine tumorigenesis (Gupta et al., 2004) . In contrast, there are conflicting reports that do not support the previous observations and suggest that ligand activation of PPARb/d attenuates colon carcinogenesis. The hypothesis that PPARb/d expression is increased by loss of regulatory control by the APC protein is uncertain since there are reports showing that PPARb/d expression is unchanged or decreased in APC min mice and/or human colon cancer patients (Chen et al., 2004; Harman et al., 2004; Matthiessen et al., 2005; Notterman et al., 2001; Orner et al., 2003) . Further, genetic deletion of the APC gene in mice leads to decreased levels of PPARb/d in the mouse colon (Reed et al., 2004) . The observations that exacerbated colon carcinogenesis is found in both the genetic (APC min mice) and chemically induced mouse models of colon carcinogenesis in the absence of PPARb/d expression Reed et al., 2004) suggests that ligand activation of PPARb/d could attenuate colon carcinogenesis. Consistent with this hypothesis, human colonocytes treated with a potent PPARb/d ligand exhibit decreased cell growth (Matthiessen et al., 2005) . Inhibition of cell growth is also observed in lung cells cultured in the presence of PPARb/d ligands (Ali et al., in press; Fukumoto et al., 2005) . Additionally, aberrant crypt foci and intestinal polyp formation in APC min mice are decreased by administration of bezafibrate (Niho et al., 2003a; Tanaka et al., 2001) , which is especially noteworthy because bezafibrate can activate PPARb/d, PPARa, and PPARc with an EC 50 ranging from 55-110 lM (Shearer and Hoekstra, 2003) . The hypothesis that COX-derived prostacyclin activates PPARb/d to increase proliferation of mutant colon cells is not supported by the recent finding that prostacyclin does not activate PPARb/d as previously thought (Fauti et al., 2006) . Thus, considerable controversy remains regarding the role of PPARb/d in colon cancer since there is evidence suggesting that PPARb/d ligands could have either positive, negative, or a combination of both effects on colon carcinogenesis. Whether these effects are mediated by PPARb/d or are influenced by PPARb/d-independent mechanisms has not been determined to date.
There is also evidence that PPARb/d ligands may influence skin carcinogenesis. Ligand activation of PPARb/d leads to terminal differentiation in skin (Schmuth et al., 2004; Tan et al., 2001; Westergaard et al., 2001) , and this effect requires a functional PPARb/d (Kim et al., 2005a) . The induction of differentiation by PPARb/d ligands has also been reported for cell types other than keratinocytes including oligodendrocytes (Saluja et al., 2001) , monocytes (Vosper et al., 2003) , and F9 cells (Werling et al., 2001) . Terminal differentiation is typically associated with inhibition of cell proliferation, and inhibition of cell growth and/or decreased expression of cyclins or PCNA is reported to occur in response to ligand activation of PPARb/d in skin or keratinocytes (Kim et al., 2005a; Tan et al., 2001; Westergaard et al., 2001) . Ligand activation of PPARb/d is also associated with the induction of apoptosis (Hatae et al., 2001; Kim et al., 2004) , but this response may be altered in the presence of inflammatory signalling (Di-Poi et al., 2002) . These combined observations suggest that ligand activation of PPARb/d induces terminal differentiation and an apoptotic-like pathway in keratinocytes, along with inhibition of cell proliferation. These characteristics are consistent with the hypothesis that PPARb/d ligands could regulate processes that will attenuate skin carcinogenesis. Consistent with this idea, PPARb/d-null mice exhibit enhanced chemically induced skin carcinogenesis . It is also noteworthy that the anti-inflammatory effects of PPARb/d ligands (Kim et al., 2005a; Lee et al., 2003; Schmuth et al., 2004; Welch et al., 2003) may also prove to be involved in the suppression of carcinogenesis. The role of PPARb/d in carcinogenesis is thus unclear and highly controversial. Further experiments using PPARb/d-null mice and specific agonists are required to definitively determine the role of PPARb/d in carcinogenesis.
CONCLUSIONS AND FUTURE DIRECTIONS
It should be clear from the previous illustrations that the mechanisms underlying the toxic effects of PPAR ligands have not all been elucidated. In some cases, the fundamental requirement for a PPAR to mediate a specific toxicity has been demonstrated with reasonable certainty. However, in many cases, not only is it unclear whether the PPAR is required, but the possible role of alternative pathways, as outlined in Figure  1 , has not been adequately examined. The potential role of species differences in signal transduction in extrapolating animal data to human risk assessment also needs attention as revealed by over thirty years of study on the PPARa agonists.
The hepatocarcinogenic effect of moderately high affinity PPARa ligands in rodents is one of the best examples of a model system where studies have shown an absolute requirement for a functional receptor (Hays et al., 2005; Peters et al., 1997a) . In response to ligand activation by fibrates, PPARa mediates increased transcription of acyl-CoA oxidase and other target genes that lead to increased cell proliferation in the liver (reviewed in Klaunig et al., 2003; Peters et al., 2005) . The increased cell proliferation in concert with DNA damaged cells (which arise through ill-defined mechanisms that may involve oxidative damage) ultimately lead to hepatocellular carcinomas (reviewed in Klaunig et al., 2003; Peters et al., 2005) . In the absence of PPARa expression, increased expression of acyl-CoA oxidase or proteins that facilitate cell proliferation such as cyclin D1 does not occur, increases in cell growth are not found, and most importantly, tumorigenesis is diminished after long-term feeding of diets containing either Wy-14,643 or bezafibrate (Hays et al., 2005; Peters et al., 1997a Peters et al., , 1998 . The lack of PPARa-mediated molecular changes and carcinogenesis in PPARa-null mice fed PPARa ligands strongly suggests that the hepatocarcinogenic effect of PPARa ligands requires the receptor, and that non-receptor mediated mechanisms are likely insignificant in causing liver cancer. However, other PPAR ligands likely produce effects that could be influenced by either both receptor-dependent and/or receptor-independent mechanisms. Unfortunately, there are limited studies that have conclusively demonstrated such a clear relationship between ligand administration and resulting toxicity such as rodent liver cancer resulting from PPARa ligands. There is more than one approach to demonstrate receptor-specificity/requirement including the use of null mouse models, siRNA gene silencing, dominant negative applications, and comparisons with antagonists and/or with multiple ligands. The use of PPAR-null mice is by far the most definitive approach that can be used to show that the receptor is required to mediate ligand-induced toxicity, and models for all three PPARs have been produced (Akiyama et al., 2002b; Barak et al., 2002; Lee et al., 1995; Peters et al., 2000) . Alternatively, mechanistic studies using specific cell types can be performed using siRNA or dominant negatives to inhibit the ligand-induced function of the receptor in an attempt to assess receptor requirements. However, these approaches have limitations and disadvantages as compared to null mice, and can only be applied at the whole animal level if transgenic mice were produced using these constructs. A tissue-specific, dominant negative PPARa transgenic mouse has been produced , and similar mouse lines expressing dominant negative PPAR constructs may also prove to be useful for this purpose. Lastly, although less convincing, one can compare the effects of different classes of ligands for a PPAR to determine whether the toxicities may or may not require the receptor. For example, the lack of overt teratogenicity associated with PPARa ligands such as clofibrate or gemfibrozil in contrast to the different developmental toxicities associated with the relatively weak PPARa ligands such as phthalate monoesters, PFOA or TCE suggest that the mechanisms underlying the latter effects are likely not mediated by PPARa but could be due to receptor-independent mechanisms. Additionally, while there is correlative evidence that increased expression of lipoprotein lipase associated with PPARa signalling could mediate PPARa ligand-induced myopathy, the role of this receptor in this toxicity has not been critically examined to date.
There are good reasons to understand whether a particular PPAR is required to mediate toxicity induced by a ligand that activates the receptor. While a chemical may activate a particular PPAR, it is possible that other mechanisms that do not require the receptor may mediate toxicity (discussed below). Additionally, if it is known that a PPAR is required to elicit toxicity (or attenuate in some cases), one can begin to examine the influence of potential species differences and/or mutations or polymorphisms in PPARs that could impact these interpretations. For example, while PPARa is required to mediate hepatocarcinogenesis in rodents, the human PPARa appears to be considerably different in function as compared to the mouse isoform. Administering PPARa ligands to mice that express the human PPARa in hepatocytes but do not express the mouse PPARa results in increased expression of proteins that catabolize lipids, but no hepatomegaly or evidence of increased hepatic cell proliferation (Cheung et al., 2004) . Further, ''humanized'' PPARa mice are resistant to the carcinogenic effects of long-term Wy-14,643 as shown by the lack of hepatocellular carcinomas found in similarly treated wild-type mice (Morimura et al., in press ). These findings have several levels of implications as related to PPAR ligand toxicities. First, these observations suggest that the effects of PPARa ligands can be both similar, and uniquely different, since both species exhibit increased lipid catabolism and reduced serum lipids, and yet only activation of the mouse PPARa can cause liver cancer induced by 643 . This suggests that it is possible that there can be large species differences in the response to PPAR ligands. Secondly, these observations support the hypothesis that PPAR ligands may lead to differential recruitment of co-effector proteins leading to significant differences in receptor function and target gene expression patterns. This suggests that any putative species difference could be due, at least in part, to this influence. Lastly, these observations also support the hypothesis that this type of species difference could exist for other PPAR ligands and other PPAR isoforms. Thus, determining the requirement of the PPAR for mediating toxicity induced by a particular PPAR ligand is essential, and is lacking for many of the examples described in this review.
Having established that a PPAR ligand causes toxicity through a receptor-mediated mechanism, what is/are the next steps required to establish a mechanism of action? Identification and characterization of the primary target genes that mediate this effect is invaluable. Unfortunately, this information is lacking for many PPAR ligand toxicities described in the literature. For example, while it is known that PPARa ligands up-regulate target genes that lead to increased hepatocellular proliferation, the precise target gene(s) that cause this effect is unknown. This information would be exceedingly important as it would provide a more definitive biomarker of PPARa ligand toxicity, and could be used to confirm the reported species difference elucidated with a humanized mouse model. Additionally, by understanding the sequence of molecular events that lead to toxicity, one can design alternative strategies to prevent or correct tissue damage. For example, as noted in this TOXICOLOGY OF PPAR LIGANDS review, PPARc ligands cause an increase in fluid volume that is associated with cardiac toxicity. This increase in fluid volume appears to be mediated by PPARc-dependent expression of renal epithelial sodium channel (Guan et al., 2005b; Zhang et al., 2005) , and this could represent a primary target gene. Thus, inhibiting sodium absorption could ameliorate this toxic effect of PPARc ligands. Similar strategies could be developed for other PPAR ligands when the primary target gene(s) and mechanisms of action have been identified.
In addition to recognizing the significance of classic ligandtranscription factor-target gene mechanism, the toxicity of PPAR ligands could also be influenced by other levels of regulation that are also receptor-dependent mechanisms. For example, do protein-protein interactions (e.g., PPAR-AP1, PPAR-NF-jB, etc) participate, does the reported repressive effect of PPARb/d modulate toxicity, or does kinase signalling interact with PPAR-mediated signalling in vivo? While these putative mechanisms could function during specific PPAR ligand-induced toxicities, they have not been examined extensively to date.
While establishing whether PPAR ligands cause toxicity through a mechanism that requires the receptor is essential, elucidating mechanisms caused by PPAR ligands that are due to receptor-independent mechanisms could also represent an important level of regulation. There are many examples of how PPAR ligands cause biological effects that are independent of the receptor. In order to establish that a particular event induced by a PPAR ligand does not require the receptor, a number of approaches have been used. Reducing or eliminating PPAR expression/function by gene targeting, antagonists, translational/transcriptional inhibitors and comparative studies with other PPAR ligands are approaches that have all been used with some degree of success. For example, some PPARc ligands can inhibit cell proliferation by inhibiting translation initiation, which may be due to depletion of intracellular calcium stores, activation of protein kinase R and subsequent inactivation of the eukaryotic initiation factor 2 (Palakurthi et al., 2001) . That these effects were not dependent on PPARc was demonstrated by performing these studies in cells that lacked expression of PPARc. Similarly, DEHP can cause PPARa-dependent testicular toxicity, but prolonged treatment with DEHP also causes pathological changes in testes that does not require PPARa (Ward et al., 1998) . Troglitazone can also cause reduced intracellular pH changes that appear to correlate with decreased DNA synthesis, and these effects occur in cells that do not express PPARc (Turturro et al., 2004) . Ligands for all three PPARs can also inhibit myeloperoxidase activity (Kim et al., 2005a) , albeit at relatively high concentration. Nonetheless, these observations suggest that PPAR ligands can interfere with enzymes, independent of the receptor. Inhibition of mitochondrial function has also been shown to occur in response to a variety of PPAR ligands, and hypothesized to contribute to PPAR ligand-induced toxicities (Feinstein et al., 2005; Scatena et al., 2003 Scatena et al., , 2004a . The significance of these receptorindependent changes and their role, if any, in modulating toxicity induced by PPAR ligands is uncertain. However, it is likely that for any given PPAR ligand, there could be both receptor-dependent and receptor-independent events that mediate their biological effects.
A number of important issues have been raised by this review. While it is clear that receptor-mediated mechanisms of toxicity have been established for some PPAR ligands, this is not always true. Indeed, ligand-induced toxicity could in theory be mediated by receptor-independent events, or by both receptor-dependent and receptor-independent mechanisms. There is evidence suggesting that PPARs may exhibit both similar and dissimilar biological functions between species, which could also be influenced by inherent differences associated with each specific PPAR ligand. Some effects may also be related more to pharmacological activation. In many cases, it is highly likely that more than one mechanism is involved. This illustrates the necessity to establish a clear mechanism of action, and evaluate these mechanisms in a variety of species, for each specific toxicity of interest. There are numerous possibilities that must be considered before grouping all PPAR ligands into one class of chemicals for safety assessment. It is possible that one PPAR ligand may cause toxicity in one tissue in one species through a receptormediated mechanism of action, while causing toxicity in FIG. 3 . Delineating receptor-dependent versus receptor-independent mechanisms of action. PPAR ligands are used for beneficial purposes but are also associated with various toxicities. By performing experiments using null mice or other gene silencing techniques, one can establish whether the effect induced by the PPAR ligand requires the receptor. Receptor-dependent and receptor-independent events may not be mutually exclusive, and there could be more than one mechanism involved in any biological effect. Subsequent experiments must also focus on delineating the specific mechanism of action, and determine whether there are species differences in this response. Lastly, it is critical that the concentration required to induce an effect (toxicity or beneficial), is within the range that can be achieved physiologically and/or therapeutically.
another species through a receptor-independent mechanism of action. Alternatively, one PPAR ligand could cause toxicity in one species through either a receptor-dependent or receptorindependent mechanism of action, while another species may be resistant to this effect for a variety of reasons. For these reasons, it is important to first determine whether the mechanism of action involves a receptor-dependent event, using gene silencing approaches (Fig. 3) . If the receptor is or is not required, supplemental studies should also consider the plethora of alternative receptor-independent mechanisms that could also participate, and address species-specific, ligandspecific and pharmacological-mediated events in the context of both receptor-dependent and receptor-independent evaluations. Considerable clinical progress has been made in the past fifteen years by targeting PPARs as molecular targets to prevent/ inhibit various diseases including dyslipidemias, diabetes and metabolic syndrome. However, PPAR ligands are also known to be associated with a variety of toxicities in a wide variety of species and cell types. It is also noteworthy that many PPAR ligands are also associated with preventing or inhibiting various toxicities. Thus, development of new types of PPAR ligands will be challenging given the complexity associated not only with the ability of the ligand to bind to and activate/ interact with PPARs, but also to produce effects that are independent of PPARs. 
